PLPhilip Lazarovici

Philip Lazarovici

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Philip Lazarovici has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Hao Jiang

    William T. Gossett Neurology Laboratories, Henry Ford Hospital, Detroit, Michigan

    4 shared publications
  • Rinat Tabakman

    Department of Pharmacology and Experimental Therapeutics, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

    4 shared publications
  • Eran Blaugrund

    Research and Development Unit, Teva Pharmaceuticals, Ltd, Kiryat Nordau, PO Box 8077, Netanya, Israel

    3 shared publications
  • Victoria Trembovler

    Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University, Jerusalem 91120, Israel

    3 shared publications
  • Mariam Monshipouri

    Patent and Trade Mark Office, Technical Center 1600

    2 shared publications
  • Robert A. Levine

    William T. Gossett Neurology Laboratories, Henry Ford Hospital, Detroit, Michigan

    2 shared publications

Latest Publications

  • Apoptotic characteristics of cell death and the neuroprotective effect of homocarnosine on pheochromocytoma PC12 cells exposed to ischemia

    by Rinat Tabakman, Hao Jiang, Robert A. Levine, Ron Kohen, Philip Lazarovici

    We recently improved an in vitro ischemic model, using PC12 neuronal cultures exposed to oxygen‐glucose deprivation (OGD) for 3 hr in a special device, followed by 18 hr of reoxygenation. The cell death induced in this ischemic model was evaluated by a series of markers: lactate dehydrogenase (LDH) release, caspase‐3 activation, presence of cyclin D1, cytochrome c leakage from the mitochondria, BAX cellular redistribution, cleavage of poly (ADP‐ribose) polymerase (PARP) to an 85‐kDa apoptotic fragment, and DNA fragmentation. The OGD insult, in the absence of reoxygenation, caused a strong activation of the mitogen‐activated protein kinase (MAPK) isoforms extracellular regulated kinase (ERK), c‐Jun NH2‐terminal kinase (JNK), and stress‐activated protein kinase (SAPK), also known asp‐38. The detection of apoptotic markers and activation of MAPKs during the ischemic insult strongly suggest that apoptosis plays an important role in the PC12 cell death. Homocarnosine, a neuroprotective histidine dipeptide, present in high concentrations in the brain, was found to provide neuroprotection, as expressed by a 40% reduction in LDH release and caspase‐3 activity at 1 mM. Homocarnosine reduced OGD activation of ERK 1, ERK 2, JNK 1, and JNK 2 by 40%, 46%, 55%, and 30%, respectively. These results suggest that apoptosis is an important characteristic of OGD‐induced neuronal death and that antioxidants, such as homocarnosine, may prevent OGD‐induced neuronal death by inhibiting the apoptotic process and/or in relation to the differential attenuation of activity of MAPKs.


  • Nerve Growth Factor Pretreatment Attenuates Oxygen and Glucose Deprivation-Induced c-Jun Amino-Terminal Kinase 1 and Stress-Activated Kinases p38α and p38β Activation and Confers Neuroprotection in the Pheochromocytoma PC12 Model

    by Rinat Tabakman, Hao Jiang, Erik Schaefer, Robert A. Levine, Philip Lazarovici

    Neurotrophins such as nerve growth factor (NGF) are considered putative neuroprotective compounds in the central nervous system. To investigate the cellular and molecular neuroprotective mechanisms of NGF under ischemia, we used a unique oxygen and glucose deprivation (OGD) device. In this system we used pheochromocytoma PC12 cells to elucidate NGF neuroprotective effect. PC12 cells were exposed to OGD, followed by addition of glucose and oxygen (OGD reperfusion). Neuronal cell death induced in this model was measured by the release of lactate dehydrogenase (LDH), activation of caspase-3 and mitogen-activated protein kinases (MAPKs), measured with specific anti-phospho-antibodies. Pretreatment of the cultures with 50 ng/mL NGF, 18 h prior to OGD insult, conferred 30% neuroprotection. However, treatment of the cultures with NGF concomitantly with the OGD insult did not result in neuroprotection. Time-course experiments showed marked activation of extracellular signal-regulated protein kinase, c-Jun N-terminal kinase (JNK), and p38 MAPK isoforms during the OGD phase but not during OGD reperfusion. Pretreatment of the cultures with 50 ng/mL NGF, 18 h prior to OGD insult, resulted in 50% attenuation of OGD-induced activation of JNK1, and 20% and 50% attenuation of OGD-induced activation of p38α and β, respectively. These findings support the notion that NGF confers neuroprotection from OGD insult, a phenomenon coincidentally related to differential inhibition of MAPK stress kinase isoforms, and provide the PC12 model as an in vitro OGD system to investigate molecular mechanisms of neurotoxicity and neuroprotection.


  • Neuroprotective effects of carnosine and homocarnosine on pheochromocytoma PC12 cells exposed to ischemia

    by Rinat Tabakman, Philip Lazarovici, Ron Kohen

    The development of neuroprotective drugs against ischemic insults is hampered by the lack of pharmacological in vitro models. We developed an ischemic model using PC12 cell cultures exposed to oxygen‐glucose‐deprivation (OGD) followed by reoxygenation (18 hr) under regular atmospheric oxygen level. The toxicity induced in this model, that is partially caused by generation of reactive oxygen species (ROS), was measured morphologically as well as by the release of lactate dehydrogenase (LDH) and the prostaglandin PGE2 from the cells. Carnosine and homocarnosine, histidine dipeptides antioxidants, found in high concentration in the brain, have been suggested to provide neuroprotection. Using the OGD model we found that 5 mM carnosine and 1 mM homocarnosine provided maximal neuroprotection of about 50% against OGD insult. This neuroprotective effect was similar to that of a known antioxidant, 4‐hydroxy‐2,2,6,6‐tetramethylpiperidine‐1‐oxyl (tempol), and was not observed in a serum‐deprivation toxicity model of PC12 cells, indicating that carnosine and homocarnosine may act as antioxidant‐neuroprotective agents in the brain. Our ischemic model may provide a useful tool for investigating the mechanisms involved in the neuroprotection afforded by histidine dipeptides.


  • A Quantitative Bioassay for Nerve Growth Factor,Using PC12 Clones Expressing Different Levels of trkA Receptors

    by Itzhak Katzir, Jashovam Shani, Keren Regev, Dalia Shabashov, Philip Lazarovici

    Nerve growth factor (NGF) is a neurotrophin required for differentiation, development, and survival of the sympathetic nervous system, with many of its biological effects being mediated via trkA receptors. There is a need for a standard quantitative bioassay for NGF, to be used in basic research and in pharmaceutical studies. The objective of the present research was to develop a selective, quantitative, and reliable bioassay for NGF, using a morphological criterion: neurite cell outgrowth. In addition, we aimed to apply the aforementioned bioassay to measure NGF administered to mice. Pheochromocytoma PC12 cell variants including wild-type cultures, and a trkA-overexpressing stable transfectant PC12-6.24-I, PC12nnr5, and PC12EN lacking trkA receptors, were used. Dose-response curves were generated with NGF β-subunit (2.5S) purified from mouse submaxillary glands. Our results demonstrated that the bioassay was sensitive to 0.3–20 ng/mL, and selective, as neurite outgrowth was not seen by any other growth factor other than NGF. In addition, variant clones PC12nnr5 and PC12EN, lacking trkA receptors, did not respond to NGF. The bioassay detected NGF in serum of mice injected with NGF. This novel developed bioassay can serve as a model system for various neuroscience purposes.


  • Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells

    by Saleh Abu-Raya, Rinat Tabakman, Eran Blaugrund, Victoria Trembovler, Philip Lazarovici


  • A Double Cysteine trkA Mutant Exhibiting Reduced NGF Binding and Delayed Erk Signaling

    by Hao Jiang, Vilen Movsesyan, Xu-Wen Liu, Yasuhiro Katagiri, Mariam Monshipouri, Philip Lazarovici

    The NGF receptor trkA is a tyrosine kinase receptor comprising an extracellular domain with a ligandbinding site, a transmembrane-spanning domain (TMD), and an intracellular domain composed of a juxtamembrane region (JMR), a tyrosine kinase domain, and a short carboxy-terminal tail. Nerve growth factor (NGF) binds and activates this receptor, leading to phosphorylation of signaling substrates involved in neuronal proliferation, differentiation, and survival. Human trkA contains one cysteine in the TMD (C423) and another, separated by 12 residues, in the JMR (C436). We hypothesized that the removal of one or both of the cysteines would affect NGF-induced signaling of the trkA receptor. Here we show that NGF induces rapid receptor autophosphorylation in a wild-type, trkA-expressing clone (WT11), in a single cysteine trkA mutants (C423T or C436A), but lower autophosphorylation activity in a double-cysteine trkA mutant (C423T/C436A). WT11 and SM cells had similar binding affinity, but that of DM cells was lower, according to the NGF radioreceptor assay. NGF-induced Erk phosphorylation was rapid in WT11 and C423T cells, but delayed in C436A and C423T/C436A cells. NGF induced [3H]thymidine incorporation into WT11 and SM cells, but had no effect on DM cells. However, basic fibroblast growth factor (bFGF) induced rapid phosphorylation of Erk1/2, and [3H]thymidine incorporation in NIH3T3, WT11, single mutant (SM), and double mutant (DM) cells, suggesting that the impaired NGF-induced Erk phosphorylation and thymidine incorporation observed in DM cells are due to the double-cysteine mutations in the trkA receptor. Cumulatively, our findings support a model in which Cys436 of the trkA is responsible for the rapid transfer of the transmembrane occupancy singnal to the SHC adaptor protein for activation of the Ras-Erk pathway and DNA synthesis.


  • NGF Stimulation of erk Phosphorylation Is Impaired by a Point Mutation in the Transmembrane Domain of trkA Receptor

    by Mariam Monshipouri, Hao Jiang, Philip Lazarovici

    The nerve growth factor (NGF) trkA receptor is a transmembrane glycoprotein composed of a large extracellular ligand-binding region connected to the cytoplasmic tyrosine kinase region by a single transmembrane domain (TMD). To explore the role of TMD in the process of receptor activation, we substituted the hydrophobic amino-acid residue valine 432 with the charged amino-acid glutamic acid (designated V432E mutant) by utilizing in vitro site-directed mutagenesis. NIH 3T3 cells lacking endogenous NGF receptors were stably transfected with a pRc/CMV vector carrying either wild-type (trkA) or mutated (V432E) receptors. Stable transfectants were shown, using 125I-NGF binding and Western-blot analysis, to express the trkA recombinant receptors. Scatchard analysis revealed similar affinity for NGF in wild-type and V432E receptors. Although the level of basal trkA receptor tyrosine phosphorylation was higher in the mutant than in the wild-type, NGF stimulation of WT 11 and V432E transfectants resulted in a rapid increase in receptor tyrosine phosphorylation and of its intracellular adaptor protein SHC. In contrast to WT 11, V432E mutants showed very low levels of NGF-, and moderate levels of FGF-induced erks phosphorylation, respectively. Collectively, these findings suggest that a single substitution (V432E) in the trkA TMD results in a selective impairment of trkA-mediated erks signaling pathway.


  • Rasagiline, a monoamine oxidase‐B inhibitor, protects NGF‐differentiated PC12 cells against oxygen‐glucose deprivation

    by Saleh Abu‐Raya, Eran Blaugrund, Victoria Trembovler, Eugenia Shilderman‐Bloch, Esther Shohami, Philip Lazarovici